Hyperkeratosis News and Research

RSS

Hyperkeratosis is the term to describe thickening of keratin in the epidermis, which is the outer layer of the skin. Keratin is a protein found in the outer layers of the skin that helps to protect the body.

Tea tree oil holds promise as a natural remedy for acne

The anti-acne properties of tea tree oil, which is widely known for its antibacterial, anti-inflammatory, and anti-oxidant properties.

14 Jun 2023

Study reveals how p62 bodies control redox-independent stress response

Cellular stress, or oxidative stress, occurs when there is a buildup of reactive oxygen species (ROS), which interferes with cellular mechanisms and can even cause damage to proteins, lipids, and DNA.

12 Jun 2023

Understanding human mycobiome commensalism and pathogenesis

Researchers explored commensalism and pathogenesis relationships in the human mycobiome.

18 Apr 2023

Acylceramides and protein-bound ceramides are vital for the formation of oral barrier in mice

Acylceramides and protein-bound ceramides are vital for the formation of the oral barrier in mice, similar to their role in skin, protecting from infection.

12 Apr 2023

Researchers make key discovery about cellular pathway linked to myriad of diseases

Researchers from the University of Dundee and the Francis Crick Institute have made a significant discovery about a cellular pathway associated with developmental defects and a myriad of diseases ranging from alopecia to colorectal cancer.

22 Mar 2018

Component of fire ant venom shows promise as a psoriasis treatment

In a new study involving laboratory mice, researchers have found that solenopsin and similar compounds could be beneficial for psoriasis.

11 Sep 2017

Cobimetinib with vemurafenib may have added benefit in melanoma with BRAF V600 mutation

Cobimetinib (trade name: Cotellic) has been approved since November 2015 in combination with vemurafenib for the treatment of adults with advanced, i.e. metastatic or unresectable, melanoma with a BRAF V600 mutation.

21 Mar 2016

GSK reports 45% survival rate in phase III study of Tafinlar in BRAF V600E mutant metastatic melanoma

GSK today announced updated results for Tafinlar (dabrafenib) from a planned analysis of the phase III BREAK-3 study in 250 patients with BRAF V600E mutant metastatic melanoma.

30 Sep 2014

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Millions of Chinese face risk of chronic arsenic poisoning

Since the 1960s, it has been known that groundwater resources in certain provinces of China are contaminated with arsenic. Estimates of the numbers of affected people have risen year by year. In the most recent survey - conducted by the Chinese Ministry of Health between 2001 and 2005 - more than 20,000 (5%) of the 445,000 wells tested showed arsenic concentrations higher than 50 -g/L.

23 Aug 2013

Tafinlar, Mekinist get FDA approval to treat patients with advanced melanoma

The U.S. Food and Drug Administration today approved two new drugs, Tafinlar (dabrafenib) and Mekinist (trametinib), for patients with advanced (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.

30 May 2013